OneSource & Bhami’s Research Lab signs licensing agreement for technology to deliver high-concentration biologics subcutaneously

OneSource Specialty Pharma, an associate company of Strides and India’s first specialty pharma pure-play CDMO (contract development and manufacturing organization), has signed a strategic licensing agreement with Bhami’s Research Laboratory (BRL).

This partnership grants OneSource access to BRL’s HILOPRO formulation technology, designed for the subcutaneous delivery of high-concentration biologic therapies. The technology reduces viscosity and facilitates the delivery of biologics such as monoclonal antibodies and fusion proteins. Under the agreement, OneSource will integrate BRL’s formulation technology into its development and manufacturing services for drug products and substances.

OneSource specializes in biologics, complex injectables, drug-device combinations, and soft gelatin capsules. With five advanced cGMP facilities and a global client base, the company maintains a strong quality compliance record, supported by successful inspections from major health authorities, including the US FDA and EU regulators.